UK High Court rejects revocation action by South Korea’s Celltrion
MLex Summary: A jointly owned Genentech and Novartis patent utilized in asthma drug XOLAIR is valid and infringed by Celltrion, the UK High Court ruled today. Celltrion’s lawsuit sought revocation of EP...To view the full article, register now.
Already a subscriber? Click here to view full article